Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IDO1 | P14902 | 17/20 | 0.40 |
| ▸ | TDO2 | P48775 | 15/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
| ▸ | ESR1 | P03372 | 1/20 | 0.37 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.37 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.37 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.37 |
| ▸ | SLC29A1 | Q99808 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7722543 | 0.92 | IDO1 (0.38) | IDO1TDO2KDM4ELMNAESR1 | |
| SCHEMBL7628637 | 0.87 | KDM4E (0.41) | IDO1TDO2KDM4ELMNAESR1 | |
| SCHEMBL7631777 | 0.84 | IDO1 (0.40) | IDO1TDO2KDM4ELMNAESR1 | |
| SCHEMBL6892458 | 0.84 | KDM4E (0.40) | IDO1TDO2KDM4ELMNAESR1 | |
| SCHEMBL6893929 | 0.84 | KDM4E (0.40) | IDO1TDO2KDM4ELMNAESR1 | |
| SCHEMBL6894075 | 0.83 | KDM4E (0.42) | IDO1TDO2KDM4ELMNAESR1 | |
| SCHEMBL7730136 | 0.82 | PLCG1 (0.40) | IDO1TDO2 | |
| SCHEMBL7648140 | 0.82 | IDO1 (0.40) | IDO1TDO2KDM4ELMNAESR1 | |
| SCHEMBL7626740 | 0.78 | KDM4E (0.41) | IDO1TDO2KDM4ELMNAESR1 | |
| SCHEMBL6897271 | 0.77 | KDM4E (0.36) | KDM4ELMNAESR1CHRM1SLC6A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6677331-B2 | HAVING SUBSTITUTED IMIDAZO(5,1-B)THIAZOLE GROUP AT 2-POSITION; MICROBIOCIDES AGAINST BETA-LACTAMASE PRODUCING BACTERIA AND RESISTANT PSEUDOMONAS | MEIJI SEIKA KAISHA, LTD. (JP) | 2004-01-13 | — | — | US | disclosed |
| US-20030149016-A1 | Novel carbapenem derivatives | KANO YUKO (JP) | 2003-08-07 | — | — | US | disclosed |
| EP-1101766-A1 | NOVEL CARBAPENEM DERIVATIVES | MEIJI SEIKA KAISHA LTD. (JP) | 2001-05-23 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030149016-A1 | Novel carbapenem derivatives | DPEP1, TMPRSS15, STK35 | IDO1 58/4885TDO2 497/4885KDM4E 1406/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.